This development is a strategic part of the company's commitment to bolstering its position in the advanced pharmaceutical intermediates segment
The company has received Form 483 with three observations
Equipped with most advanced Distributed Control System (DCS) automation technology, the facility has been set up with an investment of Rs. 200 crore
Phase 3 data expected in the second half of 2024
Investment is additive to KKR’s existing health care growth strategy
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
NRT offers 50% higher success rate in quitting smoking compared to unassisted attempts
The sale/transfer of the Company's API NonAntibiotic Business and API Antibiotic Business to Apitoria are complete
The product is expected to start contributing meaningfully to the revenue from FY25
DeltaV control system natively integrated into Sartorius Biostat STR bioreactors provide a foundation for semi-autonomous operations and up to 80% less integration time
Subscribe To Our Newsletter & Stay Updated
